Isocitrate Dehydrogenase Mutant Grade II and III Glial Neoplasms

Ingo K. Mellinghoff; Susan M. Chang; Kurt A. Jaeckle; Martin van den Bent

doi:10.1016/j.hoc.2021.08.008

Isocitrate Dehydrogenase Mutant Grade II and III Glial Neoplasms

Ingo K. Mellinghoff, Susan M. Chang, Kurt A. Jaeckle, Martin van den Bent

Neurology

Research output: Contribution to journal › Article › Academic › peer-review

6 Citations (Scopus)

32 Downloads (Pure)

Original language	English
Pages (from-to)	95-111
Number of pages	17
Journal	Hematology-Oncology Clinics of North America
Volume	36
Issue number	1
Early online date	18 Nov 2021
DOIs	https://doi.org/10.1016/j.hoc.2021.08.008
Publication status	Published - Feb 2022

Bibliographical note

Funding Information:
I.K. Mellinghoff reports serving as a consultant for Agios Pharmaceuticals, Inc, Black Diamond, DC Europa, Debiopharm, Puma Biotechnology, and Voyager, and research grants from Amgen , Eli Lilly , and General Electric . M. van den Bent reports serving as a consultant for Agios Pharmaceuticals, Karyopharm, Cellgene, Nerviano, Carthera, and Genenta. S.M. Chang reports institutional research support from Agios Pharmaceuticals .

Funding Information:
Funded by: VSNU2020.This work was supported by 1 R35 NS105109 03 (I.K. Mellinghoff), P30CA008748 (I.K. Mellinghoff), and Cycle of Survival (I.K. Mellinghoff). I.K. Mellinghoff reports serving as a consultant for Agios Pharmaceuticals, Inc, Black Diamond, DC Europa, Debiopharm, Puma Biotechnology, and Voyager, and research grants from Amgen, Eli Lilly, and General Electric. M. van den Bent reports serving as a consultant for Agios Pharmaceuticals, Karyopharm, Cellgene, Nerviano, Carthera, and Genenta. S.M. Chang reports institutional research support from Agios Pharmaceuticals.

Funding Information:
This work was supported by 1 R35 NS105109 03 (I.K. Mellinghoff), P30CA008748 (I.K. Mellinghoff), and Cycle of Survival (I.K. Mellinghoff).

Access to Document

10.1016/j.hoc.2021.08.008Licence: CC BY

Isocitrate Dehydrogenase Mutant Grade II and III Glial NeoplasmsFinal published version, 643 KBLicence: CC BY

Cite this

@article{f3bc6e0133544ad780621b867d2ccd29,

title = "Isocitrate Dehydrogenase Mutant Grade II and III Glial Neoplasms",

author = "Mellinghoff, {Ingo K.} and Chang, {Susan M.} and Jaeckle, {Kurt A.} and {van den Bent}, Martin",

note = "Funding Information: I.K. Mellinghoff reports serving as a consultant for Agios Pharmaceuticals, Inc, Black Diamond, DC Europa, Debiopharm, Puma Biotechnology, and Voyager, and research grants from Amgen , Eli Lilly , and General Electric . M. van den Bent reports serving as a consultant for Agios Pharmaceuticals, Karyopharm, Cellgene, Nerviano, Carthera, and Genenta. S.M. Chang reports institutional research support from Agios Pharmaceuticals . Funding Information: Funded by: VSNU2020.This work was supported by 1 R35 NS105109 03 (I.K. Mellinghoff), P30CA008748 (I.K. Mellinghoff), and Cycle of Survival (I.K. Mellinghoff). I.K. Mellinghoff reports serving as a consultant for Agios Pharmaceuticals, Inc, Black Diamond, DC Europa, Debiopharm, Puma Biotechnology, and Voyager, and research grants from Amgen, Eli Lilly, and General Electric. M. van den Bent reports serving as a consultant for Agios Pharmaceuticals, Karyopharm, Cellgene, Nerviano, Carthera, and Genenta. S.M. Chang reports institutional research support from Agios Pharmaceuticals. Funding Information: This work was supported by 1 R35 NS105109 03 (I.K. Mellinghoff), P30CA008748 (I.K. Mellinghoff), and Cycle of Survival (I.K. Mellinghoff). ",

year = "2022",

month = feb,

doi = "10.1016/j.hoc.2021.08.008",

language = "English",

volume = "36",

pages = "95--111",

journal = "Hematology-Oncology Clinics of North America",

issn = "0889-8588",

number = "1",

}

TY - JOUR

T1 - Isocitrate Dehydrogenase Mutant Grade II and III Glial Neoplasms

AU - Mellinghoff, Ingo K.

AU - Chang, Susan M.

AU - Jaeckle, Kurt A.

AU - van den Bent, Martin

N1 - Funding Information: I.K. Mellinghoff reports serving as a consultant for Agios Pharmaceuticals, Inc, Black Diamond, DC Europa, Debiopharm, Puma Biotechnology, and Voyager, and research grants from Amgen , Eli Lilly , and General Electric . M. van den Bent reports serving as a consultant for Agios Pharmaceuticals, Karyopharm, Cellgene, Nerviano, Carthera, and Genenta. S.M. Chang reports institutional research support from Agios Pharmaceuticals . Funding Information: Funded by: VSNU2020.This work was supported by 1 R35 NS105109 03 (I.K. Mellinghoff), P30CA008748 (I.K. Mellinghoff), and Cycle of Survival (I.K. Mellinghoff). I.K. Mellinghoff reports serving as a consultant for Agios Pharmaceuticals, Inc, Black Diamond, DC Europa, Debiopharm, Puma Biotechnology, and Voyager, and research grants from Amgen, Eli Lilly, and General Electric. M. van den Bent reports serving as a consultant for Agios Pharmaceuticals, Karyopharm, Cellgene, Nerviano, Carthera, and Genenta. S.M. Chang reports institutional research support from Agios Pharmaceuticals. Funding Information: This work was supported by 1 R35 NS105109 03 (I.K. Mellinghoff), P30CA008748 (I.K. Mellinghoff), and Cycle of Survival (I.K. Mellinghoff).

PY - 2022/2

Y1 - 2022/2

UR - http://www.scopus.com/inward/record.url?scp=85117925594&partnerID=8YFLogxK

U2 - 10.1016/j.hoc.2021.08.008

DO - 10.1016/j.hoc.2021.08.008

M3 - Article

SN - 0889-8588

VL - 36

SP - 95

EP - 111

JO - Hematology-Oncology Clinics of North America

JF - Hematology-Oncology Clinics of North America

IS - 1

ER -

Isocitrate Dehydrogenase Mutant Grade II and III Glial Neoplasms

Bibliographical note

Access to Document

Other files and links

Cite this